Cargando…

A modular and controllable T cell therapy platform for acute myeloid leukemia

Targeted T cell therapy is highly effective in disease settings where tumor antigens are uniformly expressed on malignant cells and where off-tumor on-target-associated toxicity is manageable. Although acute myeloid leukemia (AML) has in principle been shown to be a T cell-sensitive disease by the g...

Descripción completa

Detalles Bibliográficos
Autores principales:	Benmebarek, Mohamed-Reda, Cadilha, Bruno L., Herrmann, Monika, Lesch, Stefanie, Schmitt, Saskia, Stoiber, Stefan, Darwich, Abbass, Augsberger, Christian, Brauchle, Bettina, Rohrbacher, Lisa, Oner, Arman, Seifert, Matthias, Schwerdtfeger, Melanie, Gottschlich, Adrian, Rataj, Felicitas, Fenn, Nadja C., Klein, Christian, Subklewe, Marion, Endres, Stefan, Hopfner, Karl-Peter, Kobold, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7789085/ https://www.ncbi.nlm.nih.gov/pubmed/33414484 http://dx.doi.org/10.1038/s41375-020-01109-w

Ejemplares similares

Limitations in the Design of Chimeric Antigen Receptors for Cancer Therapy
por: Stoiber, Stefan, et al.
Publicado: (2019)

Chimeric Antigen Receptor–Modified T Cells and T Cell–Engaging Bispecific Antibodies: Different Tools for the Same Job
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Killing Mechanisms of Chimeric Antigen Receptor (CAR) T Cells
por: Benmebarek, Mohamed-Reda, et al.
Publicado: (2019)

Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors
por: Cadilha, Bruno L., et al.
Publicado: (2021)

PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
por: Lesch, Stefanie, et al.
Publicado: (2022)

High-affinity CD16-polymorphism and Fc-engineered antibodies enable activity of CD16-chimeric antigen receptor-modified T cells for cancer therapy
por: Rataj, Felicitas, et al.
Publicado: (2018)

Impact of the selective A2(A)R and A2(B)R dual antagonist AB928/etrumadenant on CAR T cell function
por: Seifert, Matthias, et al.
Publicado: (2022)

PD1-CD28 Fusion Protein Enables CD4+ T Cell Help for Adoptive T Cell Therapy in Models of Pancreatic Cancer and Non-hodgkin Lymphoma
por: Rataj, Felicitas, et al.
Publicado: (2018)

Chimeric antigen receptor T cells engineered to recognize the P329G-mutated Fc part of effector-silenced tumor antigen-targeting human IgG1 antibodies enable modular targeting of solid tumors
por: Stock, Sophia, et al.
Publicado: (2022)

Therapeutic Strategies for Targeting IL-1 in Cancer
por: Gottschlich, Adrian, et al.
Publicado: (2021)

Single-cell transcriptomic atlas-guided development of CAR-T cells for the treatment of acute myeloid leukemia
por: Gottschlich, Adrian, et al.
Publicado: (2023)

Paralysis of the cytotoxic granule machinery is a new cancer immune evasion mechanism mediated by chitinase 3-like-1
por: Darwich, Abbass, et al.
Publicado: (2021)

CAR T cell therapy in solid tumors: a short review
por: Umut, Öykü, et al.
Publicado: (2021)

Augmenting anti-CD19 and anti-CD22 CAR T-cell function using PD-1-CD28 checkpoint fusion proteins
por: Blaeschke, Franziska, et al.
Publicado: (2021)

Bispecific antibodies redirect synthetic agonistic receptor modified T cells against melanoma
por: Märkl, Florian, et al.
Publicado: (2023)

Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
por: Lorenzini, Theo, et al.
Publicado: (2023)

T cells armed with the C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours
por: Lesch, Stefanie, et al.
Publicado: (2021)

The PI3K∂-Selective Inhibitor Idelalisib Induces T- and NK-Cell Dysfunction Independently of B-Cell Malignancy-Associated Immunosuppression
por: Rohrbacher, Lisa, et al.
Publicado: (2021)

SIRPα-αCD123 fusion antibodies targeting CD123 in conjunction with CD47 blockade enhance the clearance of AML-initiating cells
por: Tahk, Siret, et al.
Publicado: (2021)

Transwell migration assay to interrogate human CAR-T cell chemotaxis
por: Oner, Arman, et al.
Publicado: (2022)

C-C chemokine receptor type-4 transduction of T cells enhances interaction with dendritic cells, tumor infiltration and therapeutic efficacy of adoptive T cell transfer
por: Rapp, Moritz, et al.
Publicado: (2015)

Rationale for Combining Bispecific T Cell Activating Antibodies With Checkpoint Blockade for Cancer Therapy
por: Kobold, Sebastian, et al.
Publicado: (2018)

Advances in cancer immunotherapy 2019 – latest trends
por: Kruger, Stephan, et al.
Publicado: (2019)

CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

Correction to: CD33 BiTE(®) molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells
por: Marcinek, Anetta, et al.
Publicado: (2023)

T cell-derived interleukin-22 drives the expression of CD155 by cancer cells to suppress NK cell function and promote metastasis
por: Briukhovetska, Daria, et al.
Publicado: (2023)

Microphthalmia-Associated Transcription Factor (MITF) Regulates Immune Cell Migration into Melanoma
por: Wiedemann, Gabriela M, et al.
Publicado: (2018)

Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells
por: Lichtenegger, Felix S., et al.
Publicado: (2018)

CAR T Cells Targeting Membrane-Bound Hsp70 on Tumor Cells Mimic Hsp70-Primed NK Cells
por: Bashiri Dezfouli, Ali, et al.
Publicado: (2022)

Dual-targeting triplebody 33-3-19 mediates selective lysis of biphenotypic CD19(+) CD33(+) leukemia cells
por: Roskopf, Claudia C., et al.
Publicado: (2016)

SIRPα-antibody fusion proteins stimulate phagocytosis and promote elimination of acute myeloid leukemia cells
por: Ponce, Laia Pascual, et al.
Publicado: (2017)

Enhanced Chimeric Antigen Receptor T Cell Therapy through Co-Application of Synergistic Combination Partners
por: Stock, Sophia, et al.
Publicado: (2022)

Migratory Engineering of T Cells for Cancer Therapy
por: Michaelides, Stefanos, et al.
Publicado: (2022)

Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment
por: Huynh, Duc, et al.
Publicado: (2022)

Structure of Actin-related protein 8 and its contribution to nucleosome binding
por: Gerhold, Christian B., et al.
Publicado: (2012)

Dual-targeting triplebody 33-16-123 (SPM-2) mediates effective redirected lysis of primary blasts from patients with a broad range of AML subtypes in combination with natural killer cells
por: Braciak, Todd A., et al.
Publicado: (2018)

The macrophage migration inhibitory factor (MIF)-homologue D-dopachrome tautomerase is a therapeutic target in a murine melanoma model
por: Kobold, Sebastian, et al.
Publicado: (2013)

Teaching an old dog new tricks: next-generation CAR T cells
por: Tokarew, Nicholas, et al.
Publicado: (2018)

Interleukins in cancer: from biology to therapy
por: Briukhovetska, Daria, et al.
Publicado: (2021)

Long non-coding RNAs in cancer stem cells
por: Schwerdtfeger, Melanie, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9m61mj8o99tr77hjbqcb9imk9l